The effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes
Özet
Background: The aim of this study was to compare the alterations in intraocular pressure (IOP) values during the early postoperative period after intravitreal ranibizumab, aflibercept, or dexamethasone implant injections. Material/Methods: In this retrospective study, a total of 188 patients were grouped into 3 groups: the ranibizumab group, the aflibercept group, and the dexamethasone group. Ocular axial length (AXL) and anterior chamber depth (ACD) were measured in the pre-injection period. IOP was measured just before the injection at 1 minute,10 minutes, 1 hour, 1 day, and 1 month after injection. Results: There was a transient peak in the ranibizumab group and the aflibercept group at 1 minute that started to decrease at 10 minutes and IOP values returned to preoperative values at approximately 1 hour. Similar alterations were also determined for the dexamethasone group with a lesser increase noted. In the correlation analysis, only alterations in IOP levels at 1 minute were negatively correlated with preoperative AXL values. There was not any correlation between preoperative AXL or ACD values and IOP alterations at any other time points. Conclusions: There was a sudden, transient increase in IOP values after intravitreal ranibizumab or aflibercept injections; which return to normal values in a short time without requirement of any medical treatments. This transient peak was determined to be negatively correlated with the preoperative AXL. © Med Sci Monit,.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Karakurt, Yucel | |
| dc.contributor.author | Ucak, Turgay | |
| dc.contributor.author | Taslı, Gamze | |
| dc.contributor.author | Agcayazı, Burcu | |
| dc.contributor.author | İcel, Erel | |
| dc.contributor.author | Yılmaz, Hayati | |
| dc.date.accessioned | 2026-10-18T20:29:08.494855557Z | |
| dc.date.available | 2026-10-18T20:29:08.494855557Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Background: The aim of this study was to compare the alterations in intraocular pressure (IOP) values during the early postoperative period after intravitreal ranibizumab, aflibercept, or dexamethasone implant injections. Material/Methods: In this retrospective study, a total of 188 patients were grouped into 3 groups: the ranibizumab group, the aflibercept group, and the dexamethasone group. Ocular axial length (AXL) and anterior chamber depth (ACD) were measured in the pre-injection period. IOP was measured just before the injection at 1 minute,10 minutes, 1 hour, 1 day, and 1 month after injection. Results: There was a transient peak in the ranibizumab group and the aflibercept group at 1 minute that started to decrease at 10 minutes and IOP values returned to preoperative values at approximately 1 hour. Similar alterations were also determined for the dexamethasone group with a lesser increase noted. In the correlation analysis, only alterations in IOP levels at 1 minute were negatively correlated with preoperative AXL values. There was not any correlation between preoperative AXL or ACD values and IOP alterations at any other time points. Conclusions: There was a sudden, transient increase in IOP values after intravitreal ranibizumab or aflibercept injections; which return to normal values in a short time without requirement of any medical treatments. This transient peak was determined to be negatively correlated with the preoperative AXL. © Med Sci Monit,. | |
| dc.identifier.doi | 10.12659/msm.910923 | |
| dc.identifier.eissn | 1643-3750 | |
| dc.identifier.endpage | 9025 | |
| dc.identifier.issn | 1234-1010 | |
| dc.identifier.pmcid | PMC6301255 | |
| dc.identifier.pmid | 30542050 | |
| dc.identifier.scopus | 2-s2.0-85058591515 | |
| dc.identifier.startpage | 9019 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/14341 | |
| dc.identifier.volume | 24 | |
| dc.identifier.wos | WOS:000453264500001 | |
| dc.language.iso | en | |
| dc.publisher | International Scientific Information, Inc. | |
| dc.relation.ispartof | Medical Science Monitor | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Axial length, eye | |
| dc.subject | Intraocular pressure | |
| dc.subject | Intravitreal injections | |
| dc.subject | Aged | |
| dc.subject | Aged, 80 and over | |
| dc.subject | Angiogenesis Inhibitors | |
| dc.subject | Antibodies, Monoclonal, Humanized | |
| dc.subject | Dexamethasone | |
| dc.subject | Female | |
| dc.subject | Humans | |
| dc.subject | Macular Degeneration | |
| dc.subject | Male | |
| dc.subject | Middle Aged | |
| dc.subject | Postoperative Care | |
| dc.subject | Ranibizumab | |
| dc.subject | Receptors, Vascular Endothelial Growth Factor | |
| dc.subject | Recombinant Fusion Proteins | |
| dc.subject | Retrospective Studies | |
| dc.subject | Vascular Endothelial Growth Factor A | |
| dc.subject | Visual Acuity | |
| dc.subject | aflibercept | |
| dc.subject | angiogenesis inhibitor | |
| dc.subject | fusion protein | |
| dc.subject | monoclonal antibody | |
| dc.subject | vasculotropin A | |
| dc.subject | vasculotropin receptor | |
| dc.subject | adult | |
| dc.subject | age related macular degeneration | |
| dc.subject | angiography | |
| dc.subject | anterior eye chamber depth | |
| dc.title | The effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 12 | |
| rdl.citation.wos | 9 | |
| rdl.department | Department of Ophthalmology, Erzincan University, Faculty of Medicine, Erzincan, Turkey. | Department of Ophthalmology, Erzincan Mengücek Gazi Education and Research Hospital, Erzincan, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
